Press release
May 26, 2016

Sosei Announces Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan

Tokyo, Japan 26 May 2016: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces that the US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) in connection with the global collaboration agreement, executed on 7 April 2016, by Sosei’s subsidiary Heptares Therapeutics Ltd with Allergan’s subsidiary, Allergan Pharmaceuticals International Limited to develop and commercialise a broad portfolio of novel subtype-selective muscarinic receptor agonists for the treatment of major neurological disorders, including Alzheimer’s disease.

With completion of the applicable waiting period under the HSR Act, the collaboration agreement with Allergan is effective as of 24 May 2016 under the terms previously announced on 7 April 2016, including the payment to Heptares of a $125 million upfront cash payment.